Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 356 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... February 19, 2020 Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... March 3, 2025 Hiding in plain sight: How we can use immune cells to... February 9, 2023 EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Load more HOT NEWS 6 Things That Helped Me Think Positively During Cancer: A Patient... ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia The director’s cut: How Dr Catherine Elliott sees the future of...
